Saturday, 7 November 2026European Markets

PETRONOR E&P Stock Jump Before The Weekend, Outperforms Market

Loading stream...

(VIANEWS) - The Market ended the session with PETRONOR E&P (PNOR.OL) jumping 9.25% to kr11.58 on Friday while Oslo Børs Benchmark Index_GI jumped 1.46% to kr1,418.73.

PETRONOR E&P's last close was kr10.60, 5.58% higher than its 52-week high of kr10.04.

About PETRONOR E&P

PetroNor E&P ASA operates as an independent oil and gas exploration and production company in countries offshore West Africa. The company holds exploration and production assets, which includes the PNGF Sud licenses in Congo Brazzaville, the A4 license in The Gambia, the Sinapa (Block 2) and Esperança (Blocks 4A and 5A) licenses in Guinea-Bissau, the Rufisque Offshore Profond and Senegal Offshore Sud Profond in Senegal, and OML-113 in Nigeria. PetroNor E&P ASA was founded in 2017 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, PETRONOR E&P has a trailing twelve months EPS of kr3.8.

PE Ratio

PETRONOR E&P has a trailing twelve months price to earnings ratio of 3.05. Meaning, the purchaser of the share is investing kr3.05 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 41.19%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 20.4%, now sitting on 187.33M for the twelve trailing months.

More news about PETRONOR E&P (PNOR.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com